Company / Interest Expense
Arbutus Biopharma Corp Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$459.0K
FY2023
5-year range
$459.0K / $2.9M
FY2019-FY2023
Trend
-73.4%
vs FY2022
Sector context
#37 of 44
Health Care
What the data says
Arbutus Biopharma Corp's interest expense of $459,000 is lower than 84% of companies in the Health Care sector (FY2023). Improved from $3M to $459,000 over the past 2 years.
Based on SEC 10-K filings.
$459,000 in FY2023 with a 5-year CAGR of +12.0%.
Improved from $3M to $459,000 over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -39.8%
- 5-Year CAGR
- +12.0%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 44This company $459.0K Sector average $291.0M
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +12.0%, indicating consistent growth.
- In FY2023, interest expense decreased 73.4% year-over-year.
- Ranks #37 out of 44 companies in the Health Care sector.
- Peak interest expense was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $459.0K | -73.4% |
| FY2022 | $1.7M | -39.6% |
| FY2021 | $2.9M | +35.5% |
| FY2020 | $2.1M | +832.7% |
| FY2019 | $226.0K | -13.4% |
| FY2018 | $261.0K | +0.0% |
| FY2017 | $261.0K | - |
| FY2016 | $0 | - |
As of FY2023 · SEC 10-K · Updated Jul 2, 2026